Search Results 631-640 of 18369 for alopecia

1. Genetic Analysis in Blood and Tumor Samples From Patients With Advanced or Metastatic Estrogen Receptor Positive and HER2 Negative Breast Cancer Receiving Palbociclib and Endocrine Therapy - Mayo Clinic

   Toxicities related to all prior anticancer therapies must have resolved or stabilized, apart from alopecia and peripheral neuropathy. Note: Peripheral ...

2. Cabozantinib and Nivolumab in Treating Patients With Advanced, Recurrent or Metastatic Endometrial Cancer - Mayo Clinic

   Patients who have not recovered from adverse events attributed to prior anti-cancer therapy (i.e. have residual toxicities > grade 1, except for alopecia, ...

3. Radiation Therapy with Durvalumab or Cetuximab to Treat Patients with Locoregionally Advanced Head and Neck Cancer who Cannot Take Cisplatin - Mayo Clinic

   Patients with vitiligo or alopecia;; Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement;; Any chronic skin ...

4. A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer - Mayo Clinic

   * Toxicities from previous anti-cancer therapies that have not resolved to baseline levels or to Grade 1 or less except for alopecia and peripheral neuropathy.

5. Phase III Study Of Datopotamab Deruxtecan Versus Docetaxel In Previously Treated TROP2-positive Advanced Non-squamous NSCLC Without AGA - Mayo Clinic

   Participation eligibility · Persistent toxicities caused by previous anti-cancer therapy, excluding alopecia, not yet improved to Grade ≤ 1 or baseline. · Has ...

6. A Study of Vaccine Therapy in Treating Patients with Malignant Peripheral Nerve Sheath Tumors that are Recurrent or Cannot Be Removed by Surgery - Mayo Clinic

   4.0 of prior chemotherapy regardless of interval since last treatment except alopecia and neuropathy; Requiring blood product support; Patient has CNS ...

7. Laser resurfacing - Doctors & Departments - Mayo Clinic

   ... Alopecia areata, Oral ulcerative condition, Facial volume loss, Vulvar disorder. Show more areas of focus for Alison J. Bruce, M.B., Ch.B.

8. A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency - Mayo Clinic

   Adverse effect of prior therapy not resolved to CTCAE Grade 1 or below with the exception of alopecia. Ongoing Grade 2 non-hematologic toxicity related to ...

9. A Study to Evaluate the Effectiveness and Safety of Camidanlumab Tesirine (ADCT-301) in Patients with Relapsed or Refractory Hodgkin Lymphoma - Mayo Clinic

   0]) from acute non-hematologic toxicity (except ≤ Grade 2 neuropathy or alopecia), due to previous therapy, prior to screening. Hodgkin lymphoma (HL) with ...

10. A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab - Mayo Clinic

    However, alopecia or other Grade ≤ adverse events (AEs) not constituting a safety risk based on Investigator's judgement are acceptable. Diagnosis of any ...